Oventus Medical Ltd. announced the Canadian launch of the O2Vent® Optima device which treats both the potentially fatal condition, obstructive sleep apnoea (OSA) and snoring. The device launch in Canada follows the successful completion of a controlled market release, with early results demonstrating strong patient acceptance. The O2Vent® Optima is the newest product in the O2Vent® oral device range within Oventus' Sleep Treatment Platform. Its Canadian launch follows the news in January this year, that the O2Vent® Optima had been launched in the Australian market. The O2Vent® Optima is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and incorporates the proprietary Oventus Airway Technology to improve the effectiveness of oral appliance therapy. This device is lighter than the original O2Vent® and less complex to make. The combination of reduced material costs and reduced manufacturing times lowers the cost of goods and will shorten timeframes on delivery of devices to patients. The O2Vent® Optima is the first of two new products coming to market in 2019. The US product launch is expected in second quarter of calendar year 2019, pending 510 (k) regulatory clearance from the US FDA. The second product is a valve that integrates with select O2Vent® devices to naturally improve airflow and airway stability. The valve is called the ExVentTM and has been clinically proven to dramatically increase the success rates of traditional mouthguard devices for sleep apnoea sufferers.